AiXin Life International, Inc.

Overview

AiXin Colorado is a Colorado holding company that conducts substantially all operations through its Chinese operating subsidiaries. The company focuses on health and wellness products for China’s middle class, including nutritional supplements, traditional Chinese remedies, functional products, and related foods and drinks. Primary operating channels include company-owned pharmacies, direct marketing by a field team, large multi-artist marketing events, wholesale, online channels, and marketing/distribution services for other manufacturers. Key assets include a multi-channel distribution model, the AixinZhonghong direct marketing team, and a hotel facility in Chengdu used for education and marketing.

Corporate and operating structure

• Chinese operating companies are wholly owned through HK AiXin International Group Co., Limited (AiXin HK), which is owned by AiXin (BVI) International Group, Ltd. (AiXin BVI).
• AiXin Colorado is the offshore holding company and does not directly own substantive business operations in China.
• Chinese operating companies named in filings:
  • Chengdu AiXinZhonghong Biological Technology Co., Ltd
  • Chengdu AiXin Shangyan Hotel Management Co. Ltd.
  • Chengdu Aixintang Tang Hai Chuan Hai Chuan Da Pharmacy Co., Ltd (and affiliated entities, collectively “Chengdu Aixintang Pharmacies”)
  • Yunnan Runcangsheng Technology Co., Ltd (Runcangsheng)

Acquisitions and real estate

• September 2021: Acquired nine pharmacies in Chengdu; eight pharmacies currently operate.
• September 2022: Acquired Yunnan Runcangsheng, which provides manufacturing, R&D, and wholesale capabilities and includes a large production facility and planting facilities.
• February 6, 2024: Entered into a lease for a hotel in Bandzhuyuan Town, Xindu District, Chengdu (approximately 18,000 square meters).
• Lease term for the Bandzhuyuan hotel: February 29, 2024 to April 15, 2034.
• March 31, 2024: Terminated an existing hotel lease in Jinniu District, Chengdu (originally acquired July 2021).

Business activities and offerings

• Core product categories: health and wellness products, including rhino king, goat milk-derived colostrum powder, tong li ke, ganmaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules. Some products are developed in-house or supplied by Yunnan Runcangsheng.
• Runcangsheng provides R&D, manufacturing, extraction, and wholesale distribution capabilities and supports multiple brands and planting facilities for key ingredients.
• Manufacturing and product development staff include scientists, nutritionists, formulators, and quality control personnel responsible for product development and processing of traditional Chinese medicines and modern formulations. Manufacturing operations are designed to meet applicable GMP, ISO, and HACCP standards.
• Marketing and distribution approach includes company-owned offices and pharmacies, a field sales team, large-scale marketing events, wholesale distribution, and online sales.
• The field sales team engages customers directly and uses purchasing history databases to support targeted recommendations and wellness regimens.
• Loyalty programs and incentives (for example, purchase discounts, meals, and travel) support customer acquisition and peer-to-peer distribution.
• The company provides marketing and distribution services to other health product manufacturers through AixinZhonghong.

Customer engagement and education

• The company emphasizes a differentiated customer experience that includes personal coaching, education, and solution-based selling.
• Educational events and seminars, held at the company’s hotel facilities and other venues, are used to educate staff and customers and to build customer loyalty.

Hotel as a marketing and education venue

• The Bandzhuyuan hotel site (approximately 18,000 square meters) functions as a marketing and education hub with meeting rooms and guest facilities intended for seminars and wellness events.

Pharmacy network

• Eight pharmacies operate in Chengdu under the Chengdu Aixintang Pharmacies structure and are integrated with the company’s marketing events and office channels.

Employees

• As of May 7, 2026, total employees: approximately 116
  • Administrative: 26
  • Finance: 13
  • Manufacturing: 16
  • Marketing: 57
  • R&D: 4

Financial snapshot

• Net income (loss):
  • 2025: net loss of $2,042,463
  • 2024: net loss of $2,768,341
• Cash and liquidity:
  • Cash and cash equivalents decreased from $62,310 on January 1, 2025 to $20,751 on December 31, 2025.
• Working capital:
  • Working capital deficit of $7,476,418 as of December 31, 2025.
• The company states it relies on external financing (debt or equity) to fund operations if positive cash flow is not achieved and identifies risks related to competition, regulatory compliance, RMB currency fluctuations, and cross-border regulatory matters.

Facilities and principal properties

• Yunnan Runcangsheng manufacturing center: 2,946 square meters, including R&D centers, extraction facilities, preparation workshops, storage, and planting facilities for key ingredients.
• Bandzhuyuan hotel facility: approximately 18,000 square meters in Bandzhuyuan Town, Xindu District, Chengdu; includes lobby, external shops, restaurants/tea shop, meeting rooms, guest rooms, parking, and hotel equipment.
• Pharmacies: eight locations in Chengdu operated under the Chengdu Aixintang Pharmacies structure.

Key products and intellectual property

• Primary products: rhino king, colostrum powder from goat’s milk, tong li ke, ganmaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules.
• The company has pursued trademark and patent registrations in China; rights and protection may vary by jurisdiction.

Summary

AiXin Life International operates a vertically integrated health and wellness platform in China through its PRC subsidiaries. Its operations combine manufacturing (via Yunnan Runcangsheng), distribution (pharmacy network and direct marketing), and marketing services for other manufacturers. The company uses an omni-channel sales approach—offline offices and pharmacies, live events, a field sales force, and online channels—and maintains a hotel facility in Chengdu for education and marketing. The business employs approximately 116 people, operates eight pharmacies, and maintains a manufacturing facility in Yunnan. Financial results reported net losses in 2024 and 2025 and a working capital deficit as of year-end 2025.